patientMpower Ltd, Dublin, Ireland.
Irish Lung Fibrosis Association, Dublin, Ireland.
JMIR Mhealth Uhealth. 2020 Nov 20;8(11):e16158. doi: 10.2196/16158.
Daily home-based spirometry in idiopathic pulmonary fibrosis (IPF) has been shown to be feasible and clinically informative. The patientMpower app facilitates home-based spirometry along with home-based monitoring of IPF-related symptoms. The patientMpower app can be downloaded to the user's mobile phone or tablet device, enabling the recording of objective and subjective data.
The aim of this paper is to report on the 1-year experience of using patientMpower with home-based spirometry by 36 participants with self-reported pulmonary fibrosis (PF) treated with usual care.
Self-selecting participants enrolled in this community-based participatory research program through a patient advocacy group in their country: Irish Lung Fibrosis Association in Ireland and PF Warriors in the United States. Disease severity was comparable with a baseline mean predicted forced vital capacity (FVC) of 64% and 62% in the Irish and US participants, respectively. Both groups of participants were allocated to identical, in-country, open-label, single-group observational studies and were provided with a Bluetooth-active Spirobank Smart spirometer integrated directly with patientMpower. Data collected via patientMpower included seated FVC (daily), breathlessness grade (modified Medical Research Council scale score), step count, medication adherence, and symptoms and impact of IPF on daily life, which were measured by a patient-reported outcome measure (PROM) scale that was specifically developed for IPF. Longitudinal patient-reported data on oximetry and oxygen consumption were also collected.
A large majority of the 36 participants reported that their experience using patientMpower was positive, and they wanted to continue its use after the initial 6-week observation. Out of 36 participants, 21 (58%) recorded home-based spirometry without prompting for ≥180 days, and 9 (25%) participants continued with recording home-based spirometry for ≥360 days.
The patientMpower app with associated Bluetooth-connected devices (eg, spirometer and pulse oximeter) offers an acceptable and accessible approach to collecting patient-reported objective and subjective data in fibrotic lung conditions.
特发性肺纤维化（IPF）的日常家庭肺量计检查已被证明是可行且具有临床意义的。patientMpower 应用程序便于进行家庭肺量计检查以及与 IPF 相关症状的家庭监测。patientMpower 应用程序可以下载到用户的移动电话或平板电脑设备上，从而能够记录客观和主观数据。
本文旨在报告使用 patientMpower 进行家庭肺量计检查的 1 年经验，该研究纳入了 36 名自我报告患有肺纤维化（PF）的患者，这些患者接受了常规护理。
通过他们所在国家的患者权益组织（爱尔兰的爱尔兰肺纤维化协会和美国的 PF 战士），自我选择的参与者参与了这项基于社区的参与式研究计划。疾病严重程度与基线平均预测用力肺活量（FVC）相当，爱尔兰和美国参与者的 FVC 分别为 64%和 62%。两组参与者均被分配到相同的、国内的、开放标签、单组观察性研究中，并提供了与 patientMpower 直接集成的蓝牙激活的 Spirobank Smart 肺量计。通过 patientMpower 收集的数据包括坐位 FVC（每日）、呼吸困难等级（改良的医学研究理事会量表评分）、步数、药物依从性以及 IPF 对日常生活的影响，这些数据通过专门为 IPF 开发的患者报告结局测量（PROM）量表进行测量。还收集了关于血氧饱和度和耗氧量的纵向患者报告数据。
大多数 36 名参与者报告称，他们使用 patientMpower 的体验是积极的，他们希望在最初的 6 周观察期后继续使用。在 36 名参与者中，有 21 名（58%）在没有提示的情况下记录了 180 天以上的家庭肺量计检查，有 9 名（25%）参与者继续记录了 360 天以上的家庭肺量计检查。
带有蓝牙连接设备（如肺量计和脉搏血氧仪）的 patientMpower 应用程序为收集纤维化肺部疾病的患者报告的客观和主观数据提供了一种可接受且便捷的方法。
